Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.41 |
| ▸ | TTK | P33981 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573272 | 1.00 | MAPT (0.45) | MAPTCCR3HRH3TTKALDH1A1 | |
| SCHEMBL5413984 | 0.90 | TTK (0.48) | HRH3TTKALDH1A1 | |
| SCHEMBL5394371 | 0.90 | TTK (0.48) | HRH3TTKALDH1A1 | |
| SCHEMBL14593807 | 0.82 | TTK (0.40) | TTKFGFR3KDRBRAF | |
| SCHEMBL5618376 | 0.82 | JAK3 (0.51) | TTKALDH1A1SMN1; SMN2KDRBRAF | |
| SCHEMBL5400841 | 0.81 | TTK (0.46) | HRH3TTK | |
| SCHEMBL5403422 | 0.81 | TTK (0.46) | HRH3TTK | |
| SCHEMBL5405261 | 0.80 | TTK (0.44) | TTKFGFR3KDRBRAF | |
| SCHEMBL5635552 | 0.80 | TTK (0.44) | HRH3TTK | |
| SCHEMBL5418767 | 0.79 | MEN1 (0.47) | TTKFGFR3KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | MAPT 3103/4885CCR3 3066/4885HRH3 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.